Persistence of treatment with conventional systemic agents for patients with psoriasis: a real-world analysis of 73,168 new-users from the French National Health Insurance database (SNDS).
Psoriasis is a chronic inflammatory skin disorder which can have a significant effect on the quality of life1 . There is currently no cure for psoriasis, but there are numerous treatments which are useful in controlling symptoms; thus, long-term treatment is usually required. Conventionals are among the oldest interventions given to clear psoriasis. Treatment persistence, a relevant indicator of therapeutic success2 , has received particular attention in the field of psoriasis, with most studies focusing on the persistence of biologics3,4 .